Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of the motor system and its wider cortical connections. Progress in therapeutic development in ALS is compromised by a lack of specific biomarkers. In this work, we describe a platform for QSM data acquisition and post-processing protocol for postmortem brains. Preliminary results of 10 brains (validated with quantitative ferritin staining) have shown that ALS brains had significant higher mean susceptibility in motor cortex than control brains, which indicates that QSM has the potential to accurately quantify iron concentration and thus serve as an imaging biomarker for ALS.
This abstract and the presentation materials are available to members only; a login is required.